Navigation Links
Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
Date:6/28/2010

: Key Market Trends 95 14 Global Gastrointestinal Disorder Therapeutics Market: Competitive Landscape 96 14.1 Overview 96 14.2 Competitive Profiling 96 14.3 GlaxoSmithKline, Inc 96 14.3.1 Overview 96 14.3.2 Business Description 96 14.4 AstraZeneca 97 14.4.1 Company Overview 97 14.4.2 AZD3355 98 14.5 Pfizer Incorporated 99 14.5.1 Overview 99 14.5.2 Business Description 99 14.6 Novartis Ag 100 14.6.1 Company Overview 100 14.6.2 Business Description 100 14.7 ChemoCentryx Inc. 101 14.7.1 Overview 101 14.7.2 Gastrointestinal Disease Portfolio 101 14.7.3 Crohn's Disease Product Portfolio 101 14.8 Bristol-Myers Squibb 102 14.8.1 Overview 102 14.8.2 Gastrointestinal Disease Portfolio 102 14.8.3 Crohn's Disease Product Portfolio 102 14.9 Abbott Laboratories 103 14.9.1 Overview 103 14.9.2 Gastrointestinal Disease Portfolio 103 14.9.3 Crohn's Disease Product Portfolio 103 14.10 XenoPort, Inc. 104 14.10.1 Company Overview 104 14.10.2 XP19986 104 14.11 Addex Pharmaceuticals 105 14.11.1 Company Overview 105 14.11.2 ADX10059 105 14.12 Vecta Ltd. (Vecta) 106 14.12.1 Company Overview 106 14.12.2 Vecam 106 14.13 Ironwood Pharmaceuticals and Forest Laboratories 107 14.13.1 Company Overview 107 14.13.2 IBS pipeline portfolio 108 14.14 Tioga Pharmaceuticals 109 14.14.1 Company Overview 109 14.14.2 IBS Pipeline Porfolio 109 14.15 Alimentary Health Ltd & P & G 111 14.15.1 Company Overview 111 14.15.2 IBS Pipeline Portfolio 111 14.15.3 Bifantis (Bifidobacterium infantis 35624) 111 14.16 Lexicon 112 14.16.1 Company Overview 112 14.16.2 IBS pipeline portfolio 112 14.16.3 LX-103 112 14.17 Salix Pharmaceuticals 113 14.17.1 Overview 113 14.17.2 Business Description 113 14.17.3 IBS pipeline portfolio 114 Xifaxan (Rifaximin) 114 14.17.4 Ulcerative Colitis pipe
'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... June 29 Sirnaomics, Inc. ( www.sirnaomics.com ) ... (Small Business Innovation Research) grants from National Cancer Institute ... Diseases  (NIAID), of National Institute of Health ... 2007, is dedicated to developing RNA interference (RNAi) therapeutics ...
... June 29, 2010 Cardio3,BioSciences, a leading Belgian biotechnology ... positive safety data and preliminary efficacy results from its,clinical trial of ... , , ... showed C-Cure to have a very good safety profile with no ...
... DALLAS, Texas , June 29, 2010 , ... - ReportsandReports Announces it Will Carry the Disease and Therapy,Review: Impetigo Market ... Browse the complete ... The Impetigo Disease and ...
Cached Biology Technology:Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 2Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 3Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 3Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 5Disease and Therapy Review: Impetigo Now Available at ReportsandReports 2Disease and Therapy Review: Impetigo Now Available at ReportsandReports 3Disease and Therapy Review: Impetigo Now Available at ReportsandReports 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 5
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded ... to develop an electrode array system that will ... works through unprecedented resolution and scale. , LLNL,s ... support President Obama,s BRAIN (Brain Research through ... effort to revolutionize our understanding of the human ...
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
Breaking Biology News(10 mins):The cultural side of science communication 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... (April 17, 2011) Michael Croft, Ph.D., a researcher ... has discovered a molecule,s previously unknown role as a ... making the molecule a promising therapeutic target for chronic ... lung conditions. A scientific paper on Dr. Croft,s ...
... WASHINGTON, D.C. April 14, 2011 ... Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) ... multiforme (GBM) brain tumors, following tumor recurrence after ... an anti-mitotic, anti-cancer therapy as patients maintain their ...
... of the world,s two best-loved flavours and demand for it ... the global food industry could be more secure, thanks to ... is a compound that comes from the vanilla bean, the ... tropical, climbing vine originally cultivated by ancient Central American civilisations ...
Cached Biology News:La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 2La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 3FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2Preserving a world favorite flavour 2
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... Mut S is a member of a class ... of the DNA sequence. Mut S plays an ... DNA ,replication, in transcription-coupled nucleotide excision repair and ... bacteria. Mut S binds to DNA specifically at ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: